BI 907872 in locally advanced/metastatic disease with MDM2 amplified, TP53 wild-type solid tumors

A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.

Disease Types: Pancreatic, Solid Tumors

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.

For More Information:

https://clinicaltrials.gov/study/NCT05512377?term=A%20Phase%20IIa%2FIIb,%20open-label,%20single-arm,%20multi-centre%20trial%20of%20BI%20907828%20for%20treatment%20of%20patients%20with%20locally%20advanced%2F%20metastatic,%20MDM2%20amplified,%20TP53%20wild-type%20biliary%20tract%20adenocarcinoma,%20pancreatic%20ductal%20adenocarcinoma,%20or%20other%20selected%20solid%20tumour&rank=1&limit=10